Skip to main content
Premium Trial:

Request an Annual Quote

Vysis Introduces DNA Probes for Identifying Genetic Abnormalities


DOWNERS GROVE, Ill.--Vysis announced the availability of its first group of TelVysion DNA probes for the detection of genetic abnormalities involving telomeres for prenatal, congenital, and cancer research. The probes utilize Vysis's fluorescence in situ hybridization (FISH) technology to visually detect translocations associated with disease. The probes were developed in connection with a research and exclusive license agreement with the University of Chicago. The complete line of Vysis's TelVysion FISH probes will consist of 82 products, with 41 probes specific to telomeric regions of each human chromosome.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.